Phase 1 MRX1 Study Delivers Strong Headline Data

All study objectives met MRX1 well tolerated, Phase 2 dosing on track to start H2 2026 Data reinforces case for therapeutic doses of MRX1 Oral Solution Further confidence on regulatory and clinical strategy LONDON, June 17, 2026 /PRNewswire/ -- Ananda Pharma Limited is a UK pharmaceutical...